Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 30 | Celldex TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 2 | 30 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma(ICING) | terminated | Phase 2 | 7 | UNICANCEROTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03463161 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy(ORKA) | terminated | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | terminated | Phase 2 | 54 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Sep 19, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | terminated | Phase 2 | 21 | Julie E. Bauman, MD, MPHOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | terminated | Phase 2 | 13 | Julie E. Bauman, MD, MPHOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | terminated | Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01285635 | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck | terminated | Phase 2 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00272181 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | terminated | Phase 2 | 15 | Sesen Bio, Inc.INDUSTRY | 2 | Dec 23, 2015 | clinicaltrials |
| NCT01305772 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN(TOP0901) | terminated | Phase 2 | 6 | Neal ReadyOTHER | 1 | Aug 29, 2014 | clinicaltrials |
| NCT01682031 | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 2 | Aug 22, 2014 | clinicaltrials |
| NCT01015664 | Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 / Phase 2 | 11 | University of Tennessee Cancer InstituteOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT01415986 | Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers | terminated | Phase 2 | 1 | University of ArkansasOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00805012 | Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) | terminated | Phase 2 | 96 | Seoul National University HospitalOTHER | 1 | Jul 26, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2023source: clinicaltrials